Coclavi 228mg solution is used to treat bacterial infections. Pack of 1 bottle.
Composition:
Amoxicillin / Clavulanic Acid
• 200 mg / 28 mg powder for oral suspension preparation;
• 400 mg / 57 mg powder for oral suspension preparation.
Therapeutic Indications:
CoClav should be used according to local official guidelines for antibiotic use and available susceptibility data.
CoClav suspension (228 mg/5 ml and 457 mg/5 ml) is indicated for the short-term treatment of the following infectious and inflammatory diseases when they are caused by amoxicillin-resistant beta-lactamase-producing strains.
In other cases, only amoxicillin should be used.
Indications include:
• Upper respiratory tract infections (including ENT infections):
• Lower respiratory tract infections:
• Urinary tract infections:
• Skin and soft tissue infections:
• Dental infections, including dentoalveolar abscesses.
The susceptibility of microorganisms to the medicine may vary depending on time and geographical region. Local susceptibility data should be considered. When necessary, microbiological samples should be collected and bacterial susceptibility testing should be performed.
Mixed infections caused by amoxicillin-sensitive organisms and beta-lactamase-producing organisms sensitive to CoClav can be treated with CoClav suspension without the addition of another antibiotic resistant to beta-lactamases.
Method of Administration and Dosage:
The dosage depends on the severity of the infection, as well as the patient’s age, body weight, and kidney function.
Storage Conditions:
Keep out of the reach of children and store in the original package.
Store in a dry place at a temperature not exceeding 25°C.
The prepared suspension should be stored in a refrigerator at 2-8°C and used within 7-10 days.
Do not freeze.
Dispensing Conditions:
Pharmaceutical product group II. Dispensed with prescription form №3.
